BIO — Biotest AG Income Statement
0.000.00%
Last trade - 00:00
- €1.69bn
- €2.30bn
- €516.10m
- 35
- 38
- 29
- 23
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 400 | 419 | 484 | 516 | 516 |
Cost of Revenue | |||||
Gross Profit | 135 | 129 | 130 | 80.7 | 125 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 390 | 420 | 486 | 563 | 533 |
Operating Profit | 10.6 | -1.2 | -1.3 | -47.1 | -16.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6 | -1.3 | -30 | -62.6 | -30.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -12.9 | -4.7 | -31.4 | -63.3 | -31.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 182 | -4.7 | -31.4 | -63.3 | -31.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 181 | -4.81 | -32.2 | -65 | -32.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.3 | -0.076 | -0.83 | -3.39 | -1.64 |
Dividends per Share |